This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.
Powerful perspectives
Industry Insight
Opportunities and challenges in oncology immunotherapy
Industry Insight
Reflections from our CEO
Industry Insight
Pancreatic cancer – our commitment to scientific advances
Industry Insight
A bold new era in global cancer drug discovery
Industry Insight
A note from our CEO
Industry Insight
Realising the potential of autotaxin therapy in cancer
Industry Insight
PI3Kδ inhibitors offer serious promise in solid tumors
Industry Insight
Emerging therapies offer hope for uveal melanoma patients
All articles
Press release
iOnctura announces FDA clearance of IND application for roginolisib, a first-in-class allosteric modulator of PI3Kδ
Press release
New research highlights potential of iOnctura strategy combining autotaxin and TGF-β inhibitors in cancer
Data & publication
Autotaxin secretion is a stromal mechanism of adaptive resistance to TGFβ inhibition in pancreatic ductal adenocarcinoma
Press coverage
Drug Discovery World — Meet the researcher: Giusy Di Conza
Data & publication
Non-clinical toxicology evaluation of the novel non-ATP competitive oral PI3 kinase delta inhibitor roginolisib
Press coverage
pharmaphorum — Realising the potential of autotaxin inhibition in cancer
Data & publication
Autotaxin inhibitor IOA-289 reduces gastrointestinal cancer progression in preclinical models
Data & publication
Autotaxin inhibition with IOA-289 decreases breast tumor growth in mice whereas knockout of autotaxin in adipocytes does not
Data & publication
TLR-X (IOA-359) attenuates steatosis and fibrosis in a preclinical NASH model
Data & publication
IOA-289, an orally available type IV autotaxin inhibitor, ameliorates steatosis and fibrosis in a progressive preclinical murine NASH model
Data & publication
Patient derived tumor cells identify mechanistically rational combinations for the PI3Kδ inhibitor roginolisib in solid and hematologic malignancies
Data & publication
Highly selective allosteric modulator of the phosphoinositide 3-kinase data (PI3Kδ) roginolisib (IOA-244) in a dose escalation study of patients with refractory/relapsed follicular lymphoma (FL)
Looking for media
resources?